FDA-Cleared Progress and Clinical Trials
Since launching in 2021, Precision Neuroscience has raised $155 million and received FDA clearance in April 2025 for part of its wireless BCI system.
The company has tested a temporary version in over 40 patients, with human trials for its permanent system expected soon.
“We want to get people back to a level of functional capacity where they can be independent, economically self-sufficient, and even hold a job,” Rapoport said.
The company is also part of the Implantable BCI Collaborative Community, an initiative developed in partnership with the FDA to responsibly advance BCI technology.
Visit Precision Neuroscience |
Modulating Brain Activity with Invasive BCI
A recent narrative review published by the National Library of Medicine emphasized the growing promise of invasive BCIs. The paper details how direct modulation of neural activity through implanted devices has helped restore motor and speech functions.
